BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld Asia
Home
» Pfizer to develop, sell antifungal treatment in Asia via Basilea deal
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Pfizer to develop, sell antifungal treatment in Asia via Basilea deal
Dec. 6, 2017
By
David Ho
No Comments
HONG KONG – Pfizer Inc. will bring Basilea Pharmaceutica Ltd.'s novel antifungal medicine to China and other major Asian markets as it works to meet a significant unmet need, one that is a leading cause of death across Asia.
BioWorld Asia